Pratiksha Pawar

Abstract

Nasopharyngeal carcinoma (NPC) is a rare type of tumor which arises from the surface and lining epithelium of nasopharynx. Management of nasopharyngeal carcinoma is one of the greatest clinical challenges but it is radiosensitive and chemosensitive; excellent tumor control can be attained with radiotherapy with or without adjuvant therapies concurrent chemoradiation therapy. This review will focus on role of neoadjuvant chemotherapy in nasopharyngeal carcinoma on disease free survival (DFS), distant metastases free survival and overall survival (OS) and systemic toxicities, indications and choice and number of cycles of regimen for neoadjuvant chemotherapy.   Keywords: Nasopharyngeal Carcinoma, Nasopharynx, Chemotherapy, Radiation Therapy, Concurrent Chemoradiotherapy, CCRT, NPC

View Article

Abstract

Mammary analogue secretory carcinoma is a rare salivary gland carcinoma which shares morphologic and immunohistochemical features with the secretory carcinoma of breast and was first proposed by Skalova in 2010 with translocation of (q13; q25), t (12; 15), subsequently giving ETV6-NTRK3 gene rearrangement. Usually, it is a benign tumor that affects the parotid gland, with slight predilection for males. The present article report a case of secretory carcinoma of right parotid gland with special emphasis on histological feature and immunohistochemistry for diagnostic purpose and its management. Differential diagnosis includes AciCC, ADC-NOS and MEC. In a review by Chiosa et al (2012) in 337 cases of salivary gland malignancy included AciCC, ADC-NOS, MEC, LGCC, non-ITAC, signet ring adenocarcinoma, PLGA and most common malignancy reclassified as MASC were AciCC (11/89), ADC-NOS (14/37), MEC (1/165). Management for MASC includes surgical excision of the lesion (either superficial or total parotidectomy) for local, less aggressive disease like for low-grade malignant salivary gland neoplasms. For more invasive, metastatic disease and positive margins- neck dissection, radiotherapy and chemotherapy are reserved. There is no standard multidisciplinary treatment protocol established due to scarcity of this disease.   Keywords: MASC, Mammary Analogue Secretory Carcinoma, S100, Mammaloglobin, ETV6­NTRK3

View Article